Menu
Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 2
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- View all (807)
- Volume 13, 2020 (20)
- Volume 12, 2019 (269)
- Volume 11, 2018 (92)
- Volume 10, 2017 (52)
- Volume 9, 2016 (45)
- Volume 8, 2015 (59)
- Volume 7, 2014 (61)
- Volume 6, 2013 (50)
- Volume 5, 2012 (41)
- Volume 4, 2011 (46)
- Volume 3, 2010 (45)
- Volume 2, 2009 (22)
- Volume 1, 2008 (5)
Archive: Volume 2, 2009
Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
Fuad Lechin, Bertha van der Dijs, Betty Pardey-Maldonado, et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:203-213
Published Date: 2 December 2009
Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy
Amy Fleischman, Erinn T Rhodes
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:185-202
Published Date: 27 November 2009
Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England
Stephen CL Gough, Nana Kragh, Uffe Jon Ploug, et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:179-184
Published Date: 3 November 2009
Disturbance of inorganic phosphate metabolism in diabetes mellitus: temporary therapeutic intervention trials
Jørn Ditzel, Hans Henrik Lervang
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:173-177
Published Date: 8 October 2009
Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes
Cyrus V Desouza, Lindsey Rentschler, Vivian Fonseca
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:165-172
Published Date: 25 September 2009
Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
Nanne Kleefstra, Johanna Hortensius, Kornelis JJ van Hateren, et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:155-163
Published Date: 9 September 2009
Potential efficacy of preparations derived from Phaseolus vulgaris in the control of appetite, energy intake, and carbohydrate metabolism
Mauro AM Carai, Noemi Fantini, Barbara Loi, et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:145-153
Published Date: 7 September 2009
Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
Peggy Soule Odegard, Anthony DeSantis
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:135-144
Published Date: 31 July 2009
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Jonathan K Reynolds
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:127-134
Published Date: 30 July 2009
Alogliptin: a new addition to the class of DPP-4 inhibitors
Radha Andukuri, Andjela Drincic, Marc Rendell
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:117-126
Published Date: 21 July 2009
Insulin glulisine in the management of diabetes
Satoru Yamada
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:111-115
Published Date: 7 July 2009
Fixed combination of repaglinide and metformin in the management of type 2 diabetes
Robert Moses
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:101-109
Published Date: 24 June 2009
p38 MAPK inhibition reduces diabetes-induced impairment of wound healing
Satyanarayana Medicherla, Scott Wadsworth, Breda Cullen, Derek Silcock, et al.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:91-100
Published Date: 23 June 2009
Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
Galina Smushkin, Adrian Vella
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:83-90
Published Date: 12 June 2009
Management of gestational diabetes mellitus
Annunziata Lapolla, Maria Grazia Dalfrà, Domenico Fedele
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:73-82
Published Date: 17 June 2009
Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
Paul Valensi
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:61-71
Published Date: 3 June 2009
Risk management in the treatment of type 2 diabetes with pioglitazone
Giuseppe Derosa, Sibilla AT Salvadeo
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:51-60
Published Date: 1 July 2009
Role and development of GLP-1 receptor agonists in the management of diabetes
Chee W Chia, Josephine M Egan
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:37-49
Published Date: 18 May 2009
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
Gregory E Peterson
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:31-36
Published Date: 15 May 2009
Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
Shannon A Miller, Erin L St Onge, J Roger Accardi
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:23-30
Published Date: 13 May 2009
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective
Ronald B Goldberg
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:11-21
Published Date: 5 May 2009
Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design
Thomas Strack, Luc Martinez, Stefano Del Prato, Larry Blonde, Burkhard Göke, et al
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:1-10
Published Date: 20 January 2009